RM Global Partners is convening this event due to the continuing concern about
the cardiovascular aspects and risks of the COVID-19 epidemic, even as lockdowns start
to recede. The distinguished panel of speakers will answer these questions and more:
What have we learned and what can we expect about the cardiovascular impact of COVID-19?
What is the clinical impact on trials and product approvals?
What was the impact of COVID-19 on the medtech ecosystem?
Featured Speakers
Dr. Michael R. Jaff (Moderator) is globally recognized as an expert on vascular medicine,
having led multiple clinical trials and founded VasCore, the largest international vascular
device imaging core lab in the field. He is Chief Medical Officer and VP of Peripheral
Interventions at a global medical device company. Dr. Jaff is the past President of the
Society for Vascular Medicine, the first incumbent of the Paul & Phyllis Fireman Endowed
Chair in Vascular Medicine at the Massachusetts General Hospital, and Professor of
Medicine at Harvard Medical School (leave of absence).
Dr. Louis Cannon is a Founder, Senior Managing Director at BioStar Capital, a
successful physician-founded medical device venture fund and accelerator. Dr. Cannon, a
former Judith Volkman Scholar in Residence, is the President of the Cardiac and Vascular
Research Center of Northern Michigan. He has served as national & international
Principal Investigator for landmark cardiovascular studies and has been repeatedly
honored as one of “America’s Top Interventional Cardiologists.”
Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital, a leading
venture capital fund focused on medical technology. Justin was previously a partner and
leader of medical technology investing at NEA, financing many successful cardiovascular
device companies, and held positions in strategy, finance and operations in Duke Univ.
Health System as it built one of the nation’s first integrated healthcare delivery systems.
Dr. Roxana Mehran is an internationally renowned interventional cardiologist, and clinical
research expert. She is Mount Sinai Professor in Cardiovascular Clinical Research and
Outcomes; Professor of Medicine (Cardiology) and Population Health Science and Policy
at the Icahn School of Medicine at Mount Sinai. Dr Mehran serves on the American
College of Cardiology (ACC) Board of Trustees and is a founder and Chief Scientific
Officer of the Cardiovascular Research Foundation (CRF). Dr Mehran is currently leading
the Lancet Commission on Women’s Cardiovascular Diseases.
Jack Springer has served in senior operating positions at Cordis/Johnson and Johnson,
and Medtronic/Invatec, along with being a board member and consultant to several other
cardiovascular device companies, including a leading medical device contract research
organization. He currently is CEO of Nectero Medical, Executive Chairman of R3
Vascular, and a managing director of RM Global.
This event has passed.